The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis

被引:5
作者
Blakeley, Jaishri O. [1 ]
Bakker, Annette [2 ]
Barker, Anne [3 ]
Clapp, Wade [4 ]
Ferner, Rosalie [5 ,6 ]
Fisher, Michael J. [7 ]
Giovannini, Marco [8 ]
Gutmann, David H. [9 ]
Karajannis, Matthias A. [10 ]
Kissil, Joseph L. [11 ]
Legius, Eric [12 ]
Lloyd, Alison C. [13 ]
Packer, Roger J. [14 ]
Ramesh, Vijaya [15 ]
Riccardi, Vincent M. [16 ]
Stevenson, David A. [17 ]
Ullrich, Nicole J. [18 ]
Upadhyaya, Meena [19 ]
Stemmer-Rachamimov, Anat [20 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Childrens Tumor Fdn, New York, NY USA
[3] Arizona State Univ, Tempe, AZ USA
[4] Indiana Univ, Indianapolis, IN 46204 USA
[5] Guys Hosp, London, England
[6] St Thomas Hosp, London, England
[7] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[8] Univ Calif Los Angeles, Los Angeles, CA USA
[9] Washington Univ, Sch Med, St Louis, MO USA
[10] NYU Med Ctr, New York, NY 10016 USA
[11] Scripps Res Inst, Jupiter, FL USA
[12] Ctr Human Genet Univ Hosp, Leuven, Belgium
[13] UCL, MRC Lab Mol Cell Biol, London, England
[14] Childrens Natl Med Ctr, Washington, DC 20010 USA
[15] Harvard Med Sch, Boston, MA USA
[16] Neurofibromatosis Inst, La Crescenta, CA USA
[17] Lucille Packard Childrens Hosp Stanford, Palo Alto, CA USA
[18] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA
[19] Cardiff Univ, Inst Canc Genet, Cardiff, S Glam, Wales
[20] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
关键词
neurofibromatosis type 1; neurofibromatosis type 2; pediatric tumors; rare disease; schwannomatosis; therapeutic discovery; PLEXIFORM NEUROFIBROMAS; VESTIBULAR SCHWANNOMAS; INHIBITION; RAS; FAMILY; GROWTH;
D O I
10.1002/ajmg.a.38239
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The Annual Children's Tumor Foundation International Neurofibromatosis Meeting is the premier venue for connecting discovery, translational and clinical scientists who are focused on neurofibromatosis types 1 and 2 (NF1 and NF2) and schwannomatosis (SWN). The meeting also features rare tumors such as glioma, meningioma, sarcoma, and neuroblastoma that occur both within these syndromes and spontaneously; associated with somatic mutations in NF1, NF2, and SWN. The meeting addresses both state of the field for current clinical care as well as emerging preclinical models fueling discovery of new therapeutic targets and discovery science initiatives investigating mechanisms of tumorigenesis. Importantly, this conference is a forum for presenting work in progress and bringing together all stakeholders in the scientific community. A highlight of the conference was the involvement of scientists from the pharmaceutical industry who presented growing efforts for rare disease therapeutic development in general and specifically, in pediatric patients with rare tumor syndromes. Another highlight was the focus on new investigators who presented new data about biomarker discovery, tumor pathogenesis, and diagnostic tools for NF1, NF2, and SWN. This report summarizes the themes of the meeting and a synthesis of the scientific discoveries presented at the conference in order to make the larger research community aware of progress in the neurofibromatoses.
引用
收藏
页码:1714 / 1721
页数:8
相关论文
共 25 条
[1]   Tumor Burden in Patients with Neurofibromatosis Types 1 and 2 and Schwannomatosis: Determination on Whole-Body MR Images [J].
Cai, Wenli ;
Kassarjian, Ara ;
Bredella, Miriam A. ;
Harris, Gordon J. ;
Yoshida, Hiroyuki ;
Mautner, Victor F. ;
Wenzel, Ralph ;
Plotkin, Scott R. .
RADIOLOGY, 2009, 250 (03) :665-673
[2]   NF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin [J].
Chiasson-MacKenzie, Christine ;
Morris, Zachary S. ;
Baca, Quentin ;
Morris, Breit ;
Coker, Joanna K. ;
Mirchev, Rossen ;
Jensen, Anne E. ;
Carey, Thomas ;
Stott, Shannon L. ;
Golan, David E. ;
McClatchey, Andrea I. .
JOURNAL OF CELL BIOLOGY, 2015, 211 (02) :391-405
[3]   PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies [J].
De Raedt, Thomas ;
Beert, Eline ;
Pasmant, Eric ;
Luscan, Armelle ;
Brems, Hilde ;
Ortonne, Nicolas ;
Helin, Kristian ;
Hornick, Jason L. ;
Mautner, Victor ;
Kehrer-Sawatzki, Hildegard ;
Clapp, Wade ;
Bradner, James ;
Vidaud, Michel ;
Upadhyaya, Meena ;
Legius, Eric ;
Cichowski, Karen .
NATURE, 2014, 514 (7521) :247-+
[4]   Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas [J].
Dewan, Ramita ;
Pemov, Alex ;
Kim, H. Jeffrey ;
Morgan, Keaton L. ;
Vasquez, Raul A. ;
Chittiboina, Prashant ;
Wang, Xiang ;
Chandrasekharappa, Settara C. ;
Ray-Chaudhury, Abhik ;
Butman, John A. ;
Stewart, Douglas R. ;
Asthagiri, Ashok R. .
NEURO-ONCOLOGY, 2015, 17 (04) :566-573
[5]   NF1 plexiform neurofibroma growth rate by volumetric MRI - Relationship to age and body weight [J].
Dombi, E. ;
Solomon, J. ;
Gillespie, A. J. ;
Fox, E. ;
Balis, F. M. ;
Patronas, N. ;
Korf, B. R. ;
Babovic-Vuksanovic, D. ;
Packer, R. J. ;
Belasco, J. ;
Goldman, S. ;
Jakacki, R. ;
Kieran, M. ;
Steinberg, S. M. ;
Widemann, B. C. .
NEUROLOGY, 2007, 68 (09) :643-647
[6]   Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas [J].
Dombi, Eva ;
Baldwin, Andrea ;
Marcus, Leigh J. ;
Fisher, Michael J. ;
Weiss, Brian ;
Kim, AeRang ;
Whitcomb, Patricia ;
Martin, Staci ;
Aschbacher-Smith, Lindsey E. ;
Rizvi, Tilat A. ;
Wu, Jianqiang ;
Ershler, Rachel ;
Wolters, Pamela ;
Therrien, Janet ;
Glod, John ;
Belasco, Jean B. ;
Schorry, Elizabeth ;
Brofferio, Alessandra ;
Starosta, Amy J. ;
Gillespie, Andrea ;
Doyle, Austin L. ;
Ratner, Nancy ;
Widemann, Brigitte C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26) :2550-2560
[7]   Birth Incidence and Prevalence of Tumor-Prone Syndromes: Estimates From a UK Family Genetic Register Service [J].
Evans, D. G. ;
Howard, E. ;
Giblin, C. ;
Clancy, T. ;
Spencer, H. ;
Huson, S. M. ;
Lalloo, F. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2010, 152A (02) :327-332
[8]   Malignant peripheral nerve sheath tumours in neurofibromatosis 1 [J].
Evans, DGR ;
Baser, ME ;
McGaughran, J ;
Sharif, S ;
Howard, E ;
Moran, A .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (05) :311-314
[9]   Management of the patient and family with neurofibromatosis 2: a consensus conference statement [J].
Evans, DGR ;
Baser, ME ;
O'Reilly, B ;
Rowe, J ;
Gleeson, M ;
Saeed, S ;
King, A ;
Huson, SM ;
Kerr, R ;
Thomas, N ;
Irving, R ;
MacFarlane, R ;
Ferner, R ;
McLeod, R ;
Moffat, D ;
Ramsden, R .
BRITISH JOURNAL OF NEUROSURGERY, 2005, 19 (01) :5-12
[10]   Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2 [J].
Farschtschi, S. ;
Merker, V. L. ;
Wolf, D. ;
Schuhmann, M. ;
Blakeley, J. ;
Plotkin, S. R. ;
Hagel, C. ;
Mautner, V. F. .
ACTA NEUROLOGICA SCANDINAVICA, 2016, 133 (06) :475-480